A20Rechallenge with cetuximab (cet) + irinotecan (iri) in...

Annals of Oncology 2017 / 10 Vol. 28; Iss. suppl_6

A20Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO

Santini, D, Cremolini, C, Salvatore, L, Lonardi, S, Dell'Aquila, E, Cattaneo, M, Loupakis, F, Rossini, D, Vincenzi, B, Ziampiri, S, Buoro, V, Tamburini, E, Basile, D, Corsi, D C, Fioroni, I, Masi, G,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx422.019
Date:
October, 2017
File:
PDF, 50 KB
english, 2017
Conversion to is in progress
Conversion to is failed